Claims for Patent: 3,957,982

Summary for Patent: 3,957,982

Title:	Method for contraception by the application of combination-type sequential preparations
Abstract:	Method of contraception in which an estrogen and a progestagen are orally administered daily for 21 days, the first 4-6 days at a low contraceptively effective daily dose, the next 4-6 days at a daily estrogen dose 1-2 times and a daily progestrogen dose 1-1.5 times that of the first 4-6 days, and for the next 9-11 days at a daily estrogen dose from that of the first 4-6 days to that of the next 4-6 days and a daily progestogen dose higher than either prior daily dose, up to 3 times that of the initial dose, followed by 7 days without hormone administration.
Inventor(s):	Lachnit-Fixson; Ursula (Berlin, DT), Pitchford; Alan G. (High Hurstwood, near Uckfield, EN)
Assignee:	Schering Aktiengesellschaft (Berlin & Bergkamen, DT)
Application Number:	05/535,575
Patent Claims:	1. A method of contraception which comprises administering for 21 successive days to a female of child-bearing age a combination of an estrogen and a progestogen, for the first 4-6 days in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 0.020-0.050 mg. of 17.alpha.-ethinylestradiol and in progestogenic activity to 0.050-0.125 mg. of d-norgestrel; for the next 4-6 days, at an estrogen daily dosage from 1-2 times the initial daily low dosage and at a progestogen daily dosage of from 1-1.5 times the dosage of the first 4-6 days; and for the next 9-11 days, at a daily estrogen dosage of from the initial daily dosage to the subsequent daily dosage and at a progestogen daily dosage higher than the previous daily dosages of up to 3 times that of the first daily dosage and corresponding in progestogenic activity to 0.100-0.250 mg. of d-norgestrel, followed by about 7 days without progestogen and estrogen administration. 2. A method according to claim 1 wherein the estrogen and progestogen are administered orally. 3. A method according to claim 1 wherein the estrogen and progestogen are administered in admixture. 4. A method according to claim 1 wherein the first combination of estrogen and progestogen is administered for 6 days, the second combination of estrogen and progestogen is administered for 5 days, the third combination of estrogen and progestogen is administered for 10 days and a placebo is administered for 7 days. 5. A method according to claim 1 wherein in at least one of the stages the estrogen is 17.alpha.-ethinylestradiol. 6. A method according to claim 5 wherein the estrogen in all three stages is 17.alpha.-ethinylestradiol. 7. A method according to claim 1 wherein in at least one of the stages the progestogen is d-norgestrel. 8. A method according to claim 7 wherein the progestogen in all three stages is d-norgestrel. 9. A method according to claim 1 wherein in at least one of the stages the progestogen is cyproterone acetate or 17.alpha.-ethinyl-19-nortestosterone acetate. 10. A method according to claim 1 wherein in all three stages the progestogen is d-norgestrel and the estrogen is 17.alpha.-ethinyl-19-nortestosterone acetate and they are administered orally in admixture. 11. A method according to claim 9 wherein 0.040 - 0.090 mg., 0.050 - 0.125 mg. and 0.100 - 0.250 mg., respectively, of d-norgestrel and 0.020 - 0.050 mg., 0.030 - 0.050 mg. and 0.025 - 0.050 mg., respectively, of 17.alpha.-ethinylestradiol are administered in the first, second and third stages. 12. The three-stage oral contraceptive composition comprising 21 separate dosage units, adapted for successive daily oral ingestion, consisting essentially of: as the first stage, 4-6 dosage units containing, in admixture with a pharmaceutically acceptable carrier, a combination of an estrogen and a progestogen at low but contraceptively effective respective dosages corresponding in activity to 0.020-0.050 mg. of 17.alpha.-ethinyl-estradiol and in progestogenic activity to 0.050-0.125 mg. of d-norgestrel followed by, as the second stage, 4-6 dosage units containing, in admixture with a pharmaceutically acceptable carrier, a combination of an estrogen at a dosage from the same to twice the dosage of the first stage, and a progestogen at a dosage from 1-1.5 times the dosage of the first stage, followed by, as the third stage, 9-11 dosage units containing, in admixture with pharmaceutically acceptable carrier, a combination of an estrogen at a dosage from that of the first stage to that of the second stage, and a progestogen at a higher dosage than the first and second stages up to three times that of the first stage and corresponding in progestogenic activity to 0.100-0.250 mg. of d-norgestrel, optionally followed by, as the fourth stage, 7 dosage units free of estrogen and progestogen. 13. A composition according to claim 12 wherein the dosage units are in the form of tablets. 14. A composition according to claim 12 wherein in at least one of the stages the estrogen is 17.alpha.-ethinylestradiol. 15. A composition according to claim 14 wherein the estrogen in all three stages is 17.alpha.-ethinylestradiol. 16. A composition according to claim 12 wherein in at least one of the stages the progestogen is d-norgestrel. 17. A composition according to claim 16 wherein the progestogen in all three stages is d-norgestrel. 18. A composition according to claim 12 wherein in at least one of the stages the progestogen is cyproterone acetate or 17.alpha.-ethinyl-19-nortestosterone acetate. 19. A composition according to claim 12 wherein in all three stages the progestogen is d-norgestrel and the estrogen is 17.alpha.-ethinyl-19-nortestosterone acetate. 20. A composition according to claim 19 wherein 0.040 - 0.090 mg., 0.050 - 0.125 mg. and 0.100 - 0.250 mg., respectively, of d-norgestrel and 0.020 - 0.050 mg., 0.030 - 0.050 mg. and 0.025 - 0.050 mg., respectively, of 17.alpha.-ethinylestradiol and in the first, second and third stages.